Sunovion

marketing | branding | print | digital

immaculate was appointed by Sunovion Pharmaceuticals Europe to launch ‘Latuda’, their new option for the treatment of adults with schizophrenia, developing a pharmaceutical strategy that brought HOPE to patients.

The campaign was developed through engaging prescribers and by asking the professional healthcare audience what the key criteria in the communication of Latuda benefits were, and how it would be best to communicate them. Out of this research and testing it became apparent that ‘HOPE’ was the key to unlocking the essence of how we introduce Latuda and align it with the aspirations of both prescribers and patients.

HOPE created a message platform that allowed immaculate to deliver core messages that ran through all communications, from campaigning to education and internal launch.

immaculate created a portfolio of marketing tools to aid in the awareness, education and sales of this new-to-market treatment. From traditional and digital advertising, e-detail aids, websites and film to events and meeting programmes. A series of printed and digital materials built upon the established creative concept was further developed for the European market, localising the campaign for this region with new patient stories.

An interactive exhibition stand helped bring the science to life, with augmented reality installations highlighting the effect of the disease on the brain and body.

what the client said: ‘Remarkable. The best effort of its kind I have ever seen’ – Sunovion CEO